Coverage and compliance of Albendazole in Mass Drug Administration in Kalaburgi district

---

Original Article

Author Details : Sharankumar Holyachi, Mallikarjun K. Biradar

Volume : 4, Issue : 2, Year : 2017

Article Page : 143-145

Suggest article by email

---

Abstract

Introduction: Parasitic intestinal worms, especially the soil trasnmitted are important public health problem in many developing countries. Poor nutritional outcomes can occur because of these infections especially in children. Yearly or biannual mass drug administration, which is inexpensive can reduce worm burden.
Objective: To assess the coverage and compliance of Albendazole in mass drug administration in Kalaburgi district
Materials and Method: This cross-sectional survey was done in one urban and three rural clusters in Kalaburgi district. Data was compiled, tabulated and analyzed using proportions.
Results: Out of the total 791 subjects, male population constituted about 47.7%. Majority of the study subjects were in the age group 16-60 years (70.0%); 75.1% subjects received drugs. Among the 594 study subjects who have received, 449(74.7%) consumed the drugs. Only 36.9% consumed drugs in front of health workers. Half of the subjects (52.4%) reported fear of side reaction as the reason for non-consumption of drug.
Recommendations: The coverage rate was 75.1% and compliance 74.7%. IEC activities should be strengthened with more emphasis on counseling the subject about importance of taking drugs and removing fear about side effects.

Keywords: Albendazole, Coverage, Compliance, Kalaburgi

How to cite : Holyachi S, Biradar M K, Coverage and compliance of Albendazole in Mass Drug Administration in Kalaburgi district. Indian J Forensic Community Med 2017;4(2):143-145

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.